Geron Announces Initiation of Janssen Phase 2/3 Clinical Trial of Imetelstat in Myelodysplastic Syndromes
January 14, 2016 07:30 ET
|
Geron Corporation
MENLO PARK, Calif., Jan. 14, 2016 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced the dosing of the first patient in a Phase 2/3 clinical trial to evaluate imetelstat in...
Geron Announces December Conference Presentation Webcasts
November 30, 2015 07:30 ET
|
Geron Corporation
MENLO PARK, Calif., Nov. 30, 2015 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced that John A. Scarlett, M.D., President and Chief Executive Officer, is scheduled to present...
Geron to Present At the Stifel Healthcare Conference
November 10, 2015 07:30 ET
|
Geron Corporation
MENLO PARK, Calif., Nov. 10, 2015 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced that John A. Scarlett, M.D., President and Chief Executive Officer, is scheduled to present at...
Geron Corporation Reports Third Quarter 2015 Financial Results
November 05, 2015 16:05 ET
|
Geron Corporation
MENLO PARK, Calif., Nov. 05, 2015 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today reported financial results for the third quarter ended September 30, 2015. For the third quarter of...
Geron Announces Presentations at American Society of Hematology Annual Meeting
November 05, 2015 09:03 ET
|
Geron Corporation
MENLO PARK, Calif., Nov. 05, 2015 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced that three abstracts describing clinical and non-clinical data on imetelstat have been...
Geron Announces Initiation of Janssen Phase 2 Clinical Trial of Imetelstat in Myelofibrosis
September 16, 2015 07:30 ET
|
Geron Corporation
MENLO PARK, Calif., Sept. 16, 2015 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced the dosing of the first patient in a Phase 2 clinical trial to evaluate imetelstat in...